Continue sua leitura
[ASCO 2014] Sarcomas
Apoio:
A equipe do MOC selecionou os abstracts de maior impacto da ASCO 2014. Veja abaixo os destaques em Sarcomass:
Sarcomas de Partes Moles
- ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS)
- NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas
- Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas
Sarcomas de Partes Moles
ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS)
Abstract No: 10501
Author(s): Nicolas Penel, Jean-Yves Blay, Olivier Mir, et al.
Conclusions: WP and WP-B are both active regimens of AS. B did not improve the outcome of AS pts. This study illustrates the importance of randomization in phase II trial. In the present trial, WP provides PFS (6.8 vs 4.0 months) and OS (>12 vs 8 months) significantly higher than previously reported in the AngioTax Study (Penel JCO 2008).
NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas
Abstract No: 10526
Author(s): Zeynep Eroglu, Hussein Abdul-Hassan Tawbi, James Hu, et al.
Conclusions: The combination of AZD and Tem appears to be an active regimen in the leiomyosarcoma subset. Emerging preclinical data revealing activation of the mTOR pathway in leiomyosarcoma development may explain this result.
Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas
Abstract No: 10502
Author(s): Sant P. Chawla, Zsuzsanna Papai, Kamalesh Sankhala, et al.
Conclusions: Aldoxorubin is more efficacious than doxorubicin in the treatment of advanced STS with an acceptable safety profile.